. 2020 Nov 13;8:e10382. doi: 10.7717/peerj.10382

Table 1. Characteristics of 40 patients with unresectable hepatocellular carcinoma who received lenvatinib after failure of sorafenib.

Characteristics
Age (median)	58 years (34–78)
Body weight	66.2 kg (44.8–109.5)
Liver cirrhosis	40 (100%)
ECOG performance status
0	6 (15.0%)
1	34 (85.0%)
Sex
Male	35 (87.5%)
Female	5 (12.5%)
Child–Pugh classification
A	31 (77.5%)
B	9 (22.5%)
BCLC classification
B	3 (7.5%)
C	37 (92.5%)
Viral hepatitis status
Hepatitis B	29 (72.5%)
Hepatitis C	7 (17.5%)
No	4 (10.0%)
Main portal vein thrombosis
Yes	11 (27.5%)
No	29 (72.5%)
Macrovascular invasion
Yes	19 (47.5%)
No	21 (52.5%)
Hepatectomy before lenvatinib
Yes	24 (60.0%)
No	16 (40.0%)
Extrahepatic spread
Yes	32 (80.0%)
No	8 (20.0%)
AFP > 400
Yes	17 (42.5%)
No	23 (57.5%)

Notes.